A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
Status:
Enrolling by invitation
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This rollover protocol allows continued access to seclidemstat (SP-2577) for patients who are
still receiving clinical benefit on completed or closed Salarius sponsored studies.